Lymphocyte response to tetanus toxin T-cell epitopes: Effects of tetanus vaccination and concurrent malaria prophylaxis

Vaccine

Volumn 17, Issue 1, 1999, Pages 59-63

  Fryauff, David J ^a   Mouzin, Eric ^a   Preston Church, L W ^b   Ratiwayanto, Sutanti ^a   Hadiputranto, Hilda ^a   Sutamihardja, Mochammad A ^a   Widjaja, Hendra ^a   Corradin, G ^c   Subianto, Budi ^d   Hoffman, Stephen L ^b  

^a US Naval Medical Research Unit No 2 Jakarta   (Indonesia)

^b NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d Provincial Health Services   (Indonesia)

Author keywords

Epitopes; Lymphocyte; Response; T cell; Tetanus; Toxin

Indexed keywords

CHLOROQUINE; DIPHTHERIA TOXOID; EPITOPE; PRIMAQUINE; TETANUS AND DIPHTHERIA TOXOIDS FOR ADULT USE; TETANUS TOXIN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALARIA; MALARIA CONTROL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TETANUS; VACCINATION;

ADULT; AMINO ACID SEQUENCE; ANTIMALARIALS; CHLOROQUINE; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOCYTE ACTIVATION; MALARIA; MALE; MOLECULAR SEQUENCE DATA; PLACEBOS; PRIMAQUINE; T-LYMPHOCYTES; TETANUS TOXIN; TETANUS TOXOID;

EID: 0032889604     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00144-3     Document Type: Article

References (20)

1. Galazka AM, Tetanus. In: Module 3: The Imunological Basis for Immunization Series. World Health Organization Expanded Programme on Immunization, WHO/EPI/GEN/93.13. WHO, Geneva, 1993, pp. 1-22.
2. Demotz S., Lanzavecchia A., Eisel U., Niemann H., Widmann C., Corradin G. Delineation of several DR-restricted tetanus toxin T cell epitopes. J. Immunol. 142:1989;394-402.
3. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:1989;2237-2242.
4. Good M.F., Maloy M.L., Lunde M.N.et al. Construction of synthetic immunogens: use of new T-helper epitope on malaria circumsporozoite protein. Science. 235:1987;1059.
5. Migliorini P., Boulanger N., Betschart B., Corradin G. Plasmodium berghei subunit vaccine: repeat synthetic peptide of circumsporozoite protein comprising T- and B-cell epitopes fails to confer immunity. Scand. J. Immunol. 31:1990;237.
6. Valmori D., Pessi A., Bianchi E., Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149:1992;717-721.
7. Fryauff D.J., Richards A.L., Baird J.K.et al. Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis. Antimicrob. Agents and Chemotherapy. 40:1996;2737-2742.
8. Bennet S., Riley E.M. The statistical analysis of data from immunoepidemiological studies. J. Imm. Meth. 146:1992;229-239.
9. Fryauff D.J., Church L.W., Richards A.L.et al. Lymphocyte response to tetanus among Indonesian men immunized with tetanus-diphtheria (Td) during extended chloroquine or primaquine prophylaxis. J. Infect. Dis. 176:1997;1644-1648.
10. Fryauff DJ, Church LW, Richards AL, Widjaja H, Mouzin E, Ratiwayanto S, Hadiputranto H, Sutamihardja MA, Richie TL, Subianto B, Tjitra E, Hoffman SL. Humoral immune response to tetanus-diphtheria (Td) vaccine given during extended use of chloroquine or primaquine prophylaxis. J. Infect. Dis. 1998 (in press).
11. Central Analysis Committee. The Data Book of the 11th International Histocompatability Workshop, Yokohama, Japan, 1991, Vol. 2, p. 807.
12. Herrera M.A., de Plata C., Gonzalez J.M., Corradin G., Herrera S. Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in Balb/c mice. Mem. Inst. Oswaldo Cruz. 89:1994;71-76.
13. Wang R., Charoenvit Y., Corradin G.et al. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 154:1995;2784-2793.
14. Charoenvit Y., Fallarme V., Rogers W.O.et al. Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Infect. and Immun. 65:1997;3430-3437.
15. Wang R., Charoenvit Y., Corradin G., De la Vega P., Franke E.D., Hoffman S.L. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFNg-dependent elimination of infected hepatocytes. J. Immunol. 157:1996;4061-4067.
16. Collins W.E., Sulllivan J.S., Morris C.L.et al. Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax. Am. J. Trop. Med. Hyg. 56:1997;200-210.
17. Yang C., Collins W.E., Xiao L.et al. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin. Vaccine. 15:1997;377-386.
18. Egan AF, Miller LH, Kaslow DC. Disulfide structure of Plasmodium falciparum may regulate the induction of protective immunity in vaccinated monkeys. 46th Annual Meeting, Am. Soc. Trop. Med. Hyg. 1997, Abstr. 100, 136.
19. Engers H.D., Godal T. Malaria vaccine development: current status. Parasitology Today. 14:1998;56-64.
20. Clyde D.F. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. Bull. Wld Hlth Org. 59:1981;391-395.